Alloy and Biogen Partner on Antisense Drug Platform
BOSTON, Massachusetts, United States, April 7, 2026 Alloy Therapeutics Inc. announced a multi-target collaboration and license agreement with Biogen...
Biogen
Advertisement
Biogen to Acquire Apellis in $5.6B Strategic Pharma Deal
CAMBRIDGE, Mass. & WALTHAM, Mass., USA — March 31, 2026 In a major biopharmaceutical industry consolidation, Biogen Inc. has...
Eisai and Biogen Report Strong LEQEMBI Long-Term Adherence Data
Copenhagen, Denmark | March 23, 2026 New real-world evidence presented at the AD/PD™ 2026 conference highlights that LEQEMBI® (lecanemab-irmb)...
FDA Accepts LEQEMBI sBLA, Expanding At-Home Alzheimer’s Therapy
Tokyo & Cambridge, Massachusetts, January 25, 2026 — Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food...
China Adds LEQEMBI to Insurance List for Early Alzheimer’s
TOKYO and CAMBRIDGE, Mass., December 8, 2025 — Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI® (lecanemab), an...
Advertisements
FDA Approves LEQEMBI IQLIK Subcutaneous Autoinjector for Maintenance Dosing in Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved LEQEMBI®...
Advertisement
